Revlimid Fails to Extend Survival in Lymphoma Study Revlimid Fails to Extend Survival in Lymphoma Study

Celgene Corp said on Monday that its flagship drug Revlimid (lenalidomide) failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. < br / > < i > Reuters Health Information < /i >
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news